Technical Analysis for ELVN - Enliven Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -0.79% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -0.79% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 19 hours ago |
| Down 3% | about 20 hours ago |
| Down 2 % | about 20 hours ago |
| Fell Below Lower Bollinger Band | about 22 hours ago |
| Fell Below Previous Day's Low | about 22 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.03 |
| 52 Week Low | 9.84 |
| Average Volume | 248,362 |
| 200-Day Moving Average | 21.29 |
| 50-Day Moving Average | 25.26 |
| 20-Day Moving Average | 28.25 |
| 10-Day Moving Average | 28.57 |
| Average True Range | 1.17 |
| RSI (14) | 53.27 |
| ADX | 33.27 |
| +DI | 21.74 |
| -DI | 18.17 |
| Chandelier Exit (Long, 3 ATRs) | 26.52 |
| Chandelier Exit (Short, 3 ATRs) | 28.11 |
| Upper Bollinger Bands | 29.40 |
| Lower Bollinger Band | 27.10 |
| Percent B (%b) | 0.23 |
| BandWidth | 8.14 |
| MACD Line | 0.80 |
| MACD Signal Line | 1.08 |
| MACD Histogram | -0.2744 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 29.83 | ||||
| Resistance 3 (R3) | 29.83 | 29.10 | 29.46 | ||
| Resistance 2 (R2) | 29.10 | 28.54 | 29.10 | 29.34 | |
| Resistance 1 (R1) | 28.37 | 28.20 | 28.00 | 28.36 | 29.22 |
| Pivot Point | 27.64 | 27.64 | 27.46 | 27.64 | 27.64 |
| Support 1 (S1) | 26.90 | 27.08 | 26.54 | 26.90 | 26.04 |
| Support 2 (S2) | 26.17 | 26.73 | 26.17 | 25.92 | |
| Support 3 (S3) | 25.44 | 26.17 | 25.80 | ||
| Support 4 (S4) | 25.43 |
